Compare GSK plc (GSK) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Hyatt Hotels Corporation — how do they compare? GSK plc trades at $52.8 (market cap $101.34B), while Hyatt Hotels Corporation trades at $190.47 (market cap $17.98B). The key difference: GSK plc is far larger — about 5.6× Hyatt Hotels Corporation's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | H | |
|---|---|---|
Market Cap | $101.34B | $17.98B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $202.09 |
52-Week Low | $36.20 | $135.01 |
Enterprise Value | $121.95B | $21.83B |
Dividend Yield | 3.49% | 0.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Hyatt Hotels (H) trades at $189.70, up 2.7% on the day, near its consensus price target of $198.20. The stock shows a neutral technical signal with bullish moving averages. Fundamentally, the company reported mixed Q1 2026 earnings, beating estimates with $0.63 EPS versus $0.565 expected, but faces profitability challenges with a negative net income margin of -0.48% for 2025. Recent corporate developments include expansion plans for a new Hyatt Regency in Tucson and active participation in investor conferences, signaling growth initiatives.
The outlook balances analyst optimism with fundamental headwinds. Wall Street maintains a 'Hold' consensus (52.08% Hold, 37.5% Buy) with a $198.20 price target, suggesting modest upside. Investment opportunities include strategic expansion and premium positioning, but risks include inconsistent profitability, negative ROE (-1.02%), and elevated leverage with debt-to-asset ratio rising to 31.2% in 2025. The stock's valuation appears rich at a P/E of 31.36, requiring sustained earnings improvement to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
